Evidence map›Paper›PMID 25757942›Full record

ArticleBMJ open2015

Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control study.

Julia Doulgere, Benjamin Otto, Maher Nassour, Gerrit Wolters-Eisfeld, Holger Rohde, Tim Magnus, Christoph Wagener, Thomas Streichert

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Julia DoulgereDepartment of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-0873-299X
Benjamin OttoDepartment of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maher NassourDepartment of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Gerrit Wolters-EisfeldDepartment of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-2984-6515
Holger RohdeDepartment of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tim MagnusDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph WagenerDepartment of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thomas StreichertDepartment of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Clinical Chemistry, University Hospital Cologne, Cologne, Germany.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate whether the adherens junction protein vascular endothelial cadherin (VE-cadherin) is released during Shiga toxin 2 producing Escherichia coli (STEC) infection with haemolytic uraemic syndrome (HUS) and thus could be used to assist diagnosis.

designUsing data from the large 2011 STEC outbreak in northern Europe, we determined VE-cadherin plasma concentrations in 356 patients distributed over three patient cohorts: patients with STEC infection accompanied by HUS (STEC-HUS), STEC patients without HUS (STEC) and control patients with diarrhoea but without STEC infection. We then looked for associations between VE-cadherin concentrations and disease severity defined by changes in lactate dehydrogenase, haemoglobin, creatinine, platelet count, haptoglobin and neurological symptoms.

settingThis study was conducted at the University Medical Center Hamburg-Eppendorf, Germany.

participants79 STEC-HUS patients, 77 STEC patients and 200 control patients were enrolled in the study.

resultsWe analysed 864 specimens (207 STEC, 449 STEC-HUS and 208 controls) in total. At admission, VE-cadherin concentration tended to be lower in STEC-HUS patients compared to other patients. However, HUS patients later showed an increase in VE-cadherin concentrations with prolonged elevation beyond remission. This pattern clearly differs from that observed in non-HUS patients.

conclusionsVE-cadherin concentrations are elevated in STEC-HUS patients and might be a biomarker reflecting endothelial damage in patients with HUS.

Indexed as

Shiga-Toxigenic Escherichia coliAdolescentAdultAgedAntigens, CDBiomarkersCadherin 5CadherinsCase-Control StudiesChildChild, PreschoolDiarrheaDisease OutbreaksEndothelium, VascularEscherichia coli InfectionsFemaleAntigens, CDBiomarkersCadherin 5CadherinsShiga Toxin 2ELISAEndothelial DamageShiga toxin 2STEC HUSVE-cadherin

Identifiers

PMID25757942
PMCPMC4360836
OpenAlexW2322489804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.